Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
Titel:
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
Auteur:
Winer, Eric P Lipatov, Oleg Im, Seock-Ah Goncalves, Anthony Muñoz-Couselo, Eva Lee, Keun Seok Schmid, Peter Tamura, Kenji Testa, Laura Witzel, Isabell Ohtani, Shoichiro Turner, Nicholas Zambelli, Stefania Harbeck, Nadia Andre, Fabrice Dent, Rebecca Zhou, Xuan Karantza, Vassiliki Mejia, Jaime Cortes, Javier